MDT-AP-0723
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 39
- os_event
- false
- age_years
- 11
- sex
- F
- new_clusters
- C4
- umap1_2d
- 3.399251395
- umap2_2d
- 4.595151879
- umap1_3d
- 1.04586076
- umap2_3d
- -0.696351523
- umap3_3d
- -1.96670143
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- ANGIOGENESIS+0.370
- COAGULATION+0.360
- INTERFERON_GAMMA_RESPONSE+0.310
- INTERFERON_ALPHA_RESPONSE+0.300
- DNA_REPAIR+0.280
- ALLOGRAFT_REJECTION+0.270
- KRAS_SIGNALING_UP+0.260
- COMPLEMENT+0.250
- OXIDATIVE_PHOSPHORYLATION+0.210
Top 10 suppressed
- MYC_TARGETS_V2-0.420
- NOTCH_SIGNALING-0.360
- WNT_BETA_CATENIN_SIGNALING-0.280
- MITOTIC_SPINDLE-0.220
- UNFOLDED_PROTEIN_RESPONSE-0.150
- APICAL_SURFACE-0.130
- ESTROGEN_RESPONSE_EARLY-0.130
- HEDGEHOG_SIGNALING-0.110
- HYPOXIA-0.100
- HEME_METABOLISM-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1159 | Med | Medulloblastoma | 0.765 |
| 2 | 3fa3af13-58f0-4c5b-b009-f6f936fb07b5 | — | — | 0.759 |
| 3 | AUR-AFR2-TTP1-A-1-1-R-A742-41 | — | C | 0.743 |
| 4 | SRR8518377 | — | C | 0.741 |
| 5 | TCGA-50-5049-01A-01R-1628-07 | — | cohortA1 | 0.738 |
| 6 | SRR8518385 | — | D | 0.730 |
| 7 | 32e82c06-81a8-4f40-8a32-2df86bf33b12 | — | — | 0.724 |
| 8 | MNG912 | — | — | 0.713 |
| 9 | TCGA-A8-A0A7-01A-11R-A00Z-07 | — | D | 0.707 |
| 10 | MDT-AP-0049 | Med | Medulloblastoma | 0.707 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.070 | Inavolisib | — uncovered |